Volume 4, Issue 3 (Summer 2023)
J Vessel Circ 2023, 4(3): 109-116 |
Back to browse issues page
Research code: IR.MUQ.REC.1395.122
Ethics code: IR.MUQ.REC.1395.122
Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Sabokbar T, Sharifipour E, Aghaali M, Pirsarabi F, Zamanloo M, Salarvand M, et al . Correlation Between Clinical Parameters and Genetic Markers of Thrombophilia in Ischemic Strokes. J Vessel Circ 2023; 4 (3) :109-116
URL: http://jvessels.muq.ac.ir/article-1-255-en.html
URL: http://jvessels.muq.ac.ir/article-1-255-en.html
Tayebeh Sabokbar * 
1, Ehsan Sharifipour2 , Mohammad Aghaali , Fariba Pirsarabi1 , Masoumeh Zamanloo3 , Motahare Salarvand1 , Marzieh Ghodrati3 , Seyed Amir Hejazi4
1, Ehsan Sharifipour2 , Mohammad Aghaali , Fariba Pirsarabi1 , Masoumeh Zamanloo3 , Motahare Salarvand1 , Marzieh Ghodrati3 , Seyed Amir Hejazi4
1- Neuroscience Research Center, Qom University of Medical Sciences, Qom, Iran.
2- Department of Neurology, School of Medicine, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3- Department of Neurology, Neuroscience Research Center, School of Medicine, Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.
4- Department of Neurology, Neuroscience Research Center, School of Medicine, Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran., Qom University of Medical Sciences, Qom, Iran
2- Department of Neurology, School of Medicine, Shohada-e-Tajrish Hospital, Shahid Beheshti University of Medical Sciences, Tehran, Iran.
3- Department of Neurology, Neuroscience Research Center, School of Medicine, Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran.
4- Department of Neurology, Neuroscience Research Center, School of Medicine, Beheshti Hospital, Qom University of Medical Sciences, Qom, Iran., Qom University of Medical Sciences, Qom, Iran
Abstract: (584 Views)
Background and Aim: A stroke is defined as the rapid loss of brain function due to a disturbance in blood supply. Age is a major risk factor for stroke, and genetic influences may be more significant in younger stroke patients. Patients with positive results should receive appropriate counseling. This study is the first to comprehensively investigate thrombophilia genes in Iranian populations with ischemic stroke. The purpose of this study was to determine the occurrence of genetic mutations linked to thrombophilia in individuals with ischemic stroke and examine their correlation with clinical parameters and the genetic markers of thrombophilia.
Materials and Methods: This cross-sectional study was conducted on 62 patients with ischemic stroke at the Department of Stroke in Shahid Beheshti Complex Hospital affiliated with the Qom University of Medical Sciences from October 2017 to October 2018. DNA extraction was done using CVD StripAssay® kits. SPSS software, version 25, was used to analyze the data and the statistical significance level was defined as P<0.05.
Results: Sixty-two patients with ischemic stroke had a mean age of 67.9±3.76 years. The prevalence of risk factors included smoking at 11.1%, hypertension at 79.4%, and previous diabetes and hyperlipidemia at 44.4%. Women exhibited a lower prevalence of risk factors. The most common mutation was the polymorphism of ACE at 82.5%. The second and third most common mutations were the polymorphism of FGB at 76.2% and the polymorphism of LTA at 71.4%. The prevalence of polymorphisms was as follows: ACE I/D 82.5%, FGB -455G>A 76.2%, LTA 804C>A 71.4%, eNOS 894G>T 52.4%, eNOS -786T>C 12.7%, Apo B R3500Q 33.3%, HPA1 a/b 31.7%, and Apo E (E2E2: 54%, E2E3: 3.2%, E2E4: 9.5%, E3E3: 14.3%, E3E4: 15.9%, E4E4: 1.6%). The relationship between the genes and age, sex, smoking, hyperlipidemia, diabetes, and hypertension was measured, but no significant relationship was found.
Conclusion: Thrombophilia risk factors were separated into high- and low-risk factors. There was no significant association between demographic characteristics, including age, sex, smoking, preexisting comorbidities, and thrombophilia (P>0.05). It is suggested to conduct studies with larger sample sizes, aimed at investigating gene-environment interactions as well as gene-gene interactions.
Materials and Methods: This cross-sectional study was conducted on 62 patients with ischemic stroke at the Department of Stroke in Shahid Beheshti Complex Hospital affiliated with the Qom University of Medical Sciences from October 2017 to October 2018. DNA extraction was done using CVD StripAssay® kits. SPSS software, version 25, was used to analyze the data and the statistical significance level was defined as P<0.05.
Results: Sixty-two patients with ischemic stroke had a mean age of 67.9±3.76 years. The prevalence of risk factors included smoking at 11.1%, hypertension at 79.4%, and previous diabetes and hyperlipidemia at 44.4%. Women exhibited a lower prevalence of risk factors. The most common mutation was the polymorphism of ACE at 82.5%. The second and third most common mutations were the polymorphism of FGB at 76.2% and the polymorphism of LTA at 71.4%. The prevalence of polymorphisms was as follows: ACE I/D 82.5%, FGB -455G>A 76.2%, LTA 804C>A 71.4%, eNOS 894G>T 52.4%, eNOS -786T>C 12.7%, Apo B R3500Q 33.3%, HPA1 a/b 31.7%, and Apo E (E2E2: 54%, E2E3: 3.2%, E2E4: 9.5%, E3E3: 14.3%, E3E4: 15.9%, E4E4: 1.6%). The relationship between the genes and age, sex, smoking, hyperlipidemia, diabetes, and hypertension was measured, but no significant relationship was found.
Conclusion: Thrombophilia risk factors were separated into high- and low-risk factors. There was no significant association between demographic characteristics, including age, sex, smoking, preexisting comorbidities, and thrombophilia (P>0.05). It is suggested to conduct studies with larger sample sizes, aimed at investigating gene-environment interactions as well as gene-gene interactions.
Type of Study: Research |
Subject:
stroke
Received: 2023/04/29 | Accepted: 2024/01/30 | Published: 2024/02/29
Received: 2023/04/29 | Accepted: 2024/01/30 | Published: 2024/02/29
References
1. Habibi-Koolaee M, Shahmoradi L, Niakan Kalhori SR, Ghannadan H, Younesi E. Prevalence of stroke risk factors and their distribution based on stroke subtypes in Gorgan: A retrospective hospital-based study-2015-2016. Neurol Res Int. 2018; 2018:2709654. [DOI:10.1155/2018/2709654] [PMID] [DOI:10.1155/2018/2709654]
2. Sudlow CL, Warlow CP. Comparable studies of the incidence of stroke and its pathological types: Results from an international collaboration. Stroke. 1997; 28(3):491-9. [DOI:10.1161/01.STR.28.3.491] [PMID] [DOI:10.1161/01.STR.28.3.491]
3. Bauduer F, Lacombe D. Factor V Leiden, prothrombin 20210A, methylenetetrahydrofolate reductase 677T, and population genetics. Mol Genet Metab. 2005; 86(1-2):91-9. [DOI:10.1016/j.ymgme.2005.04.002] [PMID] [DOI:10.1016/j.ymgme.2005.04.002]
4. Kraaijenhagen RA, Haverkamp D, Koopman MM, Prandoni P, Piovella F, Büller HR. Travel and risk of venous thrombosis. Lancet. 2000; 356(9240):1492-3. [DOI:10.1016/S0140-6736(00)02878-6] [PMID] [DOI:10.1016/S0140-6736(00)02878-6]
5. Kim DS, Burt AA, Ranchalis JE, Jarvik ER, Rosenthal EA, Hatsukami TS, et al. Novel gene-by-environment interactions: APOB and NPC1L1 variants affect the relationship between dietary and total plasma cholesterol. J Lipid Res. 2013; 54(5):1512-20. [DOI:10.1194/jlr.P035238] [PMID] [DOI:10.1194/jlr.P035238]
6. Serebruany V, Sani Y, Eisert C, Schevchuck A, Fong A, Hanley D. Effects of Aggrenox and aspirin on plasma endothelial nitric oxide synthase and oxidised low-density lipoproteins in patients after ischaemic stroke. The AGgrenox versus aspirin therapy evaluation (AGATE) biomarker substudy. Thromb Haemost. 2011; 105(1):81-7. [DOI:10.1160/TH10-05-0316] [PMID] [DOI:10.1160/TH10-05-0316]
7. Mäkelä KM, Seppälä I, Hernesniemi JA, Lyytikäinen LP, Oksala N, Kleber ME, et al. Genome-wide association study pinpoints a new functional apolipoprotein B variant influencing oxidized low-density lipoprotein levels but not cardiovascular events: AtheroRemo Consortium. Circ Cardiovasc Genet. 2013; 6(1):73-81. [DOI:10.1161/CIRCGENETICS.112.964965] [PMID] [DOI:10.1161/CIRCGENETICS.112.964965]
8. Tian YF, Zhou YP, Zhong CK, Buren B, Xu T, Li HM, et al. C-reactive protein Level, apolipoprotein B-to-apolipoprotein A-1 ratio, and risks of ischemic stroke and coronary heart disease among inner Mongolians in China. Biomed Environ Sci. 2016; 29(7):467-74. [PMID]
9. Byun YS, Yang X, Bao W, DeMicco D, Laskey R, Witztum JL, et al. Oxidized phospholipids on apolipoprotein B-100 and recurrent ischemic events following stroke or transient ischemic attack. J Am Coll Cardiol. 2017; 69(2):147-58. [DOI:10.1016/j.jacc.2016.10.057] [PMID] [DOI:10.1016/j.jacc.2016.10.057]
10. Bennet AM, Di Angelantonio E, Ye Z, Wensley F, Dahlin A, Ahlbom A, et al. Association of apolipoprotein E genotypes with lipid levels and coronary risk. JAMA. 2007; 298(11):1300-11. [DOI:10.1001/jama.298.11.1300] [PMID] [DOI:10.1001/jama.298.11.1300]
11. Hu X, Wang J, Li Y, Wu J, Qiao S, Xu S, et al. The β-fibrinogen gene 455G/A polymorphism associated with cardioembolic stroke in atrial fibrillation with low CHA2DS2-VaSc score. Sci Rep. 2017; 7(1):17517. [DOI:10.1038/s41598-017-17537-1] [PMID] [DOI:10.1038/s41598-017-17537-1]
12. Luo H, Li X, Jiang A, Zhang B, Bi P, Dong Y, et al. Associations of β-Fibrinogen Polymorphisms with the Risk of Ischemic Stroke: A meta-analysis. J Stroke Cerebrovasc Dis. 2019; 28(2):243-50. [DOI:10.1016/j.jstrokecerebrovasdis.2018.09.007] [PMID] [DOI:10.1016/j.jstrokecerebrovasdis.2018.09.007]
13. Kang MK, Kim OJ, Jeon YJ, Kim HS, Oh SH, Kim JK, et al. Interplay between polymorphisms in the endothelial nitric oxide synthase (eNOS) gene and metabolic syndrome in determining the risk of ischemic stroke in Koreans. J Neurol Sci. 2014; 344(1-2):55-9. [DOI:10.1016/j.jns.2014.06.020] [PMID] [DOI:10.1016/j.jns.2014.06.020]
14. Wei LK, Au A, Menon S, Gan SH, Griffiths LR. Clinical relevance of MTHFR, eNOS, ACE, and ApoE gene polymorphisms and serum vitamin profile among Malay patients with ischemic stroke. J Stroke Cerebrovasc Dis. 2015; 24(9):2017-25. [DOI:10.1016/j.jstrokecerebrovasdis.2015.04.011] [PMID] [DOI:10.1016/j.jstrokecerebrovasdis.2015.04.011]
15. Joshi MS, Mineo C, Shaul PW, Bauer JA. Biochemical consequences of the NOS3 Glu298Asp variation in human endothelium: Altered caveolar localization and impaired response to shear. FASEB J. 2007; 21(11):2655-63. [DOI:10.1096/fj.06-7088com] [PMID] [DOI:10.1096/fj.06-7088com]
16. Niu T, Chen X, Xu X. Angiotensin converting enzyme gene insertion/deletion polymorphism and cardiovascular disease: Therapeutic implications. Drugs. 2002; 62(7):977-93. [DOI:10.2165/00003495-200262070-00001] [PMID] [DOI:10.2165/00003495-200262070-00001]
17. Xia MM, Wang M, Jiang H, Liu Y, Ma L, Lu C, et al. Association of angiotensin-converting enzyme insertion/deletion polymorphism with the risk of atherosclerosis. J Stroke Cerebrovasc Dis. 2019; 28(6):1732-43. [DOI:10.1016/j.jstrokecerebrovasdis.2019.02.012] [PMID] [DOI:10.1016/j.jstrokecerebrovasdis.2019.02.012]
18. Schreyer SA, Vick CM, LeBoeuf RC. Loss of lymphotoxin-α but not tumor necrosis factor-α reduces atherosclerosis in mice. J Biol Chem. 2002; 277(14):12364-8. [DOI:10.1074/jbc.M111727200] [PMID] [DOI:10.1074/jbc.M111727200]
19. Trompet S, de Craen AJ, Slagboom P, Shepherd J, Blauw GJ, Murphy MB, et al. Lymphotoxin-alpha C804A polymorphism is a risk factor for stroke. The PROSPER study. Exp Gerontol. 2008; 43(8):801-5. [DOI:10.1016/j.exger.2008.04.006] [PMID] [DOI:10.1016/j.exger.2008.04.006]
20. Bentley P, Peck G, Smeeth L, Whittaker J, Sharma P. Causal relationship of susceptibility genes to ischemic stroke: Comparison to ischemic heart disease and biochemical determinants. PLoS One. 2010; 5(2):e9136. [DOI:10.1371/journal.pone.0009136] [PMID] [DOI:10.1371/journal.pone.0009136]
21. Chiasakul T, De Jesus E, Tong J, Chen Y, Crowther M, Garcia D, et al. Inherited thrombophilia and the risk of arterial ischemic stroke: A systematic review and meta‐analysis. J Am Heart Assoc. 2019; 8(19):e012877. [DOI:10.1161/JAHA.119.012877] [PMID] [DOI:10.1161/JAHA.119.012877]
22. Yaghi S, Bernstein RA, Passman R, Okin PM, Furie KL. Cryptogenic stroke: Research and practice. Circ Res. 2017; 120(3):527-540. [DOI:10.1161/CIRCRESAHA.116.308447] [PMID] [DOI:10.1161/CIRCRESAHA.116.308447]
23. Grau AJ, Weimar C, Buggle F, Heinrich A, Goertler M, Neumaier S, et al. Risk factors, outcome, and treatment in subtypes of ischemic stroke: The German stroke data bank. Stroke. 2001; 32(11):2559-66. [DOI:10.1161/hs1101.098524] [PMID] [DOI:10.1161/hs1101.098524]
24. Szolnoki Z, Somogyvári F, Kondacs A, Szabó M, Fodor L. Evaluation of the roles of the Leiden V mutation and ACE I/D polymorphism in subtypes of ischaemic stroke. J Neurol. 2001; 248(9):756-61. [DOI:10.1007/s004150170090] [PMID] [DOI:10.1007/s004150170090]
25. Sharma P. Meta-analysis of the ACE gene in ischaemic stroke. J Neurol Neurosurg Psychiatry. 1998; 64(2):227-30. [DOI:10.1136/jnnp.64.2.227] [PMID] [DOI:10.1136/jnnp.64.2.227]
26. Szolnoki Z, Melegh B. Gene-gene and gene-environment interplay represent specific susceptibility for different types of ischaemic stroke and leukoaraiosis. Curr Med Chem. 2006; 13(14):1627-34. [DOI:10.2174/092986706777441931] [PMID] [DOI:10.2174/092986706777441931]
27. Celiker G, Can U, Verdi H, Yazici AC, Ozbek N, Atac FB. Prevalence of thrombophilic mutations and ACE I/D polymorphism in Turkish ischemic stroke patients. Clin Appl Thromb Hemost. 2009; 15(4):415-20. [DOI:10.1177/1076029608315163] [PMID] [DOI:10.1177/1076029608315163]
28. Margaglione M, Celentano E, Grandone E, Vecchione G, Cappucci G, Giuliani N, et al. Deletion polymorphism in the angiotensin-converting enzyme gene in patients with a history of ischemic stroke. Arterioscler Thromb Vasc Biol. 1996; 16(2):304-9. [DOI:10.1161/01.ATV.16.2.304] [PMID] [DOI:10.1161/01.ATV.16.2.304]
29. Doi Y, Yoshinari M, Yoshizumi H, Ibayashi S, Wakisaka M, Fujishima M. Polymorphism of the angiotensin-converting enzyme (ACE) gene in patients with thrombotic brain infarction. Atherosclerosis. 1997; 132(2):145-50. [DOI:10.1016/S0021-9150(97)00080-4] [PMID] [DOI:10.1016/S0021-9150(97)00080-4]
30. Kumar A, Misra S, Kumar P, Sagar R, Prasad K. Association between beta-fibrinogen C148T gene polymorphism and risk of ischemic stroke in a north Indian population: A case-control study. Pulse. 2017 4(4):165-71. [DOI:10.1159/000449361] [PMID] [DOI:10.1159/000449361]
31. Kahrizi K, Oberkanins C, Hadavi V, Bozorgmehr B, Najmabadi H. [Study of beta-fibrinogen-455 G/A polymorphism as a genetic risk factor for cardiovascular disease in the Iranian population (Portuguese)]. Genet Third Millennium. 2010; 8(1):1957-61. [Link]
32. Lee SH, Kim MK, Park MS, Choi SM, Kim JT, Kim BC, et al. β-Fibrinogen Gene -455 G/A polymorphism in Korean ischemic stroke patients. J Clin Neurol. 2008; 4(1):17-22.[DOI:10.3988/jcn.2008.4.1.17] [PMID] [DOI:10.3988/jcn.2008.4.1.17]
33. Lam KS, Ma OC, Wat NM, Chan LC, Janus ED. Beta-fibrinogen gene G/A-455 polymorphism in relation to fibrinogen concentrations and ischaemic heart disease in Chinese patients with type II diabetes. Diabetologia. 1999; 42(10):1250-3. [DOI:10.1007/s001250051300] [PMID] [DOI:10.1007/s001250051300]
34. Zhao N, Liu X, Wang Y, Liu X, Li J, Yu L, et al. Association of inflammatory gene polymorphisms with ischemic stroke in a Chinese Han population. J Neuroinflammation. 2012; 9:162. [DOI:10.1186/1742-2094-9-162] [PMID] [DOI:10.1186/1742-2094-9-162]
35. Martiskainen M, Oksala N, Pohjasvaara T, Kaste M, Oksala A, Karhunen PJ, et al. Βeta-fibrinogen gene promoter A− 455 allele associated with poor longterm survival among 55-71 years old Caucasian women in Finnish stroke cohort. BMC Neurol. 2014; 14:137. [DOI:10.1186/1471-2377-14-137] [PMID] [DOI:10.1186/1471-2377-14-137]
| Rights and permissions | |
 |
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License. |
Owned by Qom University of Medical Sciences
Published by Qom University of Medical Sciences Press
eISSN: 2717-0357
Email: jvessels[at]muq.ac.ir
j.vessels.circul[at]gmail.com
